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Mammalian protein production platforms have had a profound impact in many areas of basic and
applied research, and an increasing number of blockbuster drugs are recombinant mammalian
proteins. With global sales of these drugs exceeding US$120 billion per year, both industry and
academic research groups continue to develop cost effective methods for producing mammalian
proteins to support pre-clinical and clinical evaluations of potential therapeutics. While a wide
range of platforms have been successfully exploited for laboratory use, the bulk of recent biologics
have been produced in mammalian cell lines due to the requirement for post translational modiﬁ-
cation and the biosynthetic complexity of the target proteins. In this review we highlight the range
of mammalian expression platforms available for recombinant protein production, as well as
advances in technologies for the rapid and efﬁcient selection of highly productive clones.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ability to produce mammalian proteins in recombinant
systems has had a profound impact in many areas of basic and
applied research, as well as the biotech sector. While academic
research groups require recombinant mammalian proteins for
functional analysis (e.g. cellular signaling pathways) and high res-
olution structure determination, the biotech sector has heavily in-
vested in the production of protein therapeutics (i.e. biologics), as a
relatively new and transformative approach to treating human dis-
eases. An increasing number of blockbuster drugs are recombinant
mammalian proteins and the United States Food and Drug Admin-
istration (FDA) has approved over 100 recombinant protein thera-
peutics to date [1]. With this success, both industry and academic
research groups continue to develop cost effective methods for
producing mammalian proteins to support pre-clinical and clinical
evaluations of potential therapeutics.
The need for multi-milligram quantities of recombinant mam-
malian protein in the academic sector is, in part, driven by focused
and team-based structural biology initiatives, such as the New York
Structural Genomics Research Consortium (NYSGRC) [2] [http://
www.nysgrc.org/psi3-cgi/index.cgi], as well as pre-clinical re-
search. The screening of 10–20 constructsmay be required to obtain
the multi-milligrams yields needed for successful structure deter-
mination [3]. As our understanding of cellular signaling pathwaysgrow, so does the need for structural characterization of the signal-
ing components and more importantly, structures of the relevant
multi-component protein assemblies. As the tools for producing
these mammalian proteins improve so does the complexity and va-
lue of the structures determined; a recent report describing the
highly sought after ternary complex of the Wnt pathway proteins,
R-spondin 1, RNF43 and LGR5, highlights this point [4].
By far the greatest demand for recombinant mammalian
proteins is for therapeutic development and applications. The pro-
duction of recombinant proteins for biopharmaceutical use is a
multi-billion dollar industry, with global sales over US$120 billion
per year and an anticipated increase to US$150 billion by 2015 [5].
Of the top nine classes of biologic drugs sold in 2011, monoclonal
antibodies (mAbs) command the highest sales (Fig. 1) and this
trend is growing [6].
While Escherichia coli (E. coli), yeast and insect cell lines are still
the preferred platforms for many protein expression groups, mam-
malian proteins often require mammalian cells for optimum yields
and activity. While a wide range of platforms have been success-
fully exploited for laboratory use, the bulk of recent biologics have
been produced in mammalian cell lines due to the requirement for
post translational modiﬁcation and the biosynthetic complexity of
the target proteins [1]. In the case of monoclonal antibodies, Chi-
nese Hamster Ovary (CHO) and NS0 (mouse myeloma) cells are
the most commonly used lines [7,8]. With the substantial growth
being realized in the area of biologics, there is a continuing
demand for new and enhanced mammalian expression platforms.
The goal of this review is to highlight the range of mammalian plat-
forms available for recombinant protein production as well as
Fig. 1. US sales ($ billions) of top nine classes of biologic drugs in 2011. Adapted from Aggarwal et al. [6].
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highly productive clones.
2. Expression platforms
2.1. CHO
The workhorse of mammalian protein production (especially at
industrial scale) is the CHO cell line, isolated by Theodore Puck in
the late 1950’s [9]. Initially selected for radiation cytogenetic stud-
ies due to their low chromosome number (2n = 22), CHO cells have
proven to be a hardy and reliable cell line in culture. Since the com-
mercial introduction of human tissue plasminogen activator (tPA)
as the ﬁrst recombinant therapeutic protein produced from mam-
malian cells [10], the annual global revenue of products from CHO
cells has increased to more than US$100 billion and continues to
grow [11]. The wide spread success of the CHO platform is due
to its unparalleled adaptability allowing for growth of these cells
at high densities in suspension cultures and ease of adaptation to
serum free conditions. There has been a great deal of improvement
in the quality and availability of chemically deﬁned, serum free
media that is devoid of animal-derived materials. These tailored
media are more cost effective, as they do not require supplementa-
tion with fetal calf serum; safer, as there is less risk of viral and
prion contamination from bovine serum; and have simpliﬁed
downstream processing requirements, as they contain fewer pro-
tein contaminants. In addition, a study in 1989 tested 44 human
pathogens (including human immunodeﬁciency virus (HIV), inﬂu-
enza, polio, herpes and measles), and found the majority of them
do not replicate in CHO cells, thus making CHOs ideal from a reg-
ulatory standpoint [12]. However, the adaptability of the CHO line
also has its drawbacks, as each production target requires the
selection of clones that exhibit the necessary phenotypic proper-
ties, including product quality/uniformity, doubling time and long
term viability, under bioprocess conditions. Even when an appro-
priate CHO production clone has been identiﬁed, phenotypic drift
(i.e. changes in the previously selected characteristics) is not
uncommon and remains a challenge [11].
While enhancing clonal stability (i.e. product uniformity) is an
area of intense study, the most signiﬁcant improvements to CHOculture have resulted from the optimization of media, feeding
strategies and downstream processing. These improvements have
resulted in yields ranging between 2 and 6 g/L for antibody prod-
ucts [13]. A particular focus of product optimization in CHO cells
is glycosylation, as it has been shown that variation in glycosyla-
tion patterns affects product stability and function, and non-natu-
ral glycoforms can be immunogenic [14–16]. This is particularly
true of the terminal galactose-a-1,3-galactose (a-Gal) epitope,
which has been demonstrated to be added to proteins produced
in murine cell lines, and is capable of inducing an immune re-
sponse in humans [17]. The importance of glycoform proﬁles in
therapeutics has been highlighted by the adverse clinical effects
associated with an induced IgE-mediated anaphylaxis response in
patients treated with the commercial antibody Erbitux (cetux-
imab), which was manufactured in a murine myeloma cell line
and possessed a-Gal epitopes [17,18]. It was thought that CHO
cells lacked the biosynthetic machinery to produce the a-Gal epi-
tope, but this assumption has been brought into question by re-
ports that CHO cells can add the a-Gal antigen to recombinant
products, as has been observed for Orencia (abatacept) [17]. There-
fore, it is essential that CHO production clones be carefully moni-
tored for product uniformity and safety in terms of glycosylation
proﬁles.
The genomic variability of CHO cells and the fact that they are
functionally hemizygous for many genes [19,20] also has certain
advantages, as it has allowed for the isolation of mutant lines with
deﬁciencies in metabolic enzymes. These mutants are dependent
on certain nutrients for survival, making them ideal for the gener-
ation of producer lines by using the deﬁciency as a selection mar-
ker. Mutants of the enzyme dihydrofolate reductase (DHFR) were
generated in this manner [21] and will be discussed below. To sup-
port further development of CHOs for protein production, a gen-
ome sequencing project was initiated in 2002 as a collaboration
between the University of Minnesota and the Bioprocessing Tech-
nology Institute of Singapore (A⁄STAR). This collaboration led to
two cDNA libraries being constructed from three CHO cell lines,
grown under different conditions, corresponding to over 4000 ex-
pressed sequence tags (ESTs) [22]. This initial study led to further
sequencing efforts under the auspices of the Consortium on Chi-
nese Hamster Ovary Cell Genomics in partnership with the Society
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tion of genetic markers associated with high productivity [12].
While there is no doubt that CHO cells will continue to be used
and developed for biopharmaceutical production, the push for gen-
erating more complex human proteins, with a better safety proﬁle,
has led to the further development of existing lines and the gener-
ation of novel human cell lines that we believe will be the plat-
forms of the future.
2.2. HEK 293
Developed almost two decades after the CHO cell line, the 293
cell line was the ﬁrst human line to be transformed using sheared
adenovirus DNA fragments of the Ad5 serotype [23]. Transforma-
tion of the human embryonic kidney (HEK) cells by viral DNA was
performed with a calcium transfection technique developed by
Graham and van der Eb [24,25]. Since its development, the 293 cell
line has become one of the most commonly used human cell lines
for protein production. There have been many variants of the origi-
nal line, such as 293N3S developed for suspension growth in biore-
actors for adenovirus production [26] and the 293S line that was
adapted to grow under serum free conditions [27]. In order to im-
prove transient gene expression (discussed below), two additional
lines were developed, the 293-T line expressing the SV40 large T-
antigen [28] and the 293-E line expressing the Epstein-Barr virus
EBNA1 protein [29]. The latter two lines support the episomal rep-
lication of plasmids containing either the SV40 origin of replication
or the EBV oriP, respectively, thereby prolonging the expression of
the target gene after transient transfection. While CHO cells have
been the workhorse of recombinant protein production, the 293
line has grown in prominence with the realization that proteins
produced in HEK cells are a closer match to naturally occurring
human proteins in terms of post translational modiﬁcation and
function [30]. Improvements in culture processes has resulted in
293-based platforms capable of supporting antibody yields exceed-
ing 1 g/L [31]. More recently the HKB11 line has been developed
which is a hybrid between the HEK 293S line and a human B cell
line, 2B8 (derived from a Burkitt’s lymphoma line) [32]. This line
combines features of the parental lines, resulting in a system that
is easy to transfect (a characteristic of 293s), with the capacity to se-
crete large amounts of protein (a characteristic of B cells). It’s utility
has been amply demonstrated in the case of human coagulation
factor VIII (which contains 25 potential N-linked glycosylation sites,
6 tyrosine sulfation sites and 7 disulﬁde bonds) with yields that are
about 8-fold higher than the parental 293 line [33].
2.3. PER.C6
The PER.C6 (Crucell) line was originally generated from human
retinoblast cells immortalized by transfection with an E1 minigene
for the cost-effective production of safe, clinical-grade recombi-
nant adenovirus vectors [34]. However this cell line also has
several features that make it ideal for recombinant protein produc-
tion: PER.C6 were generated in compliance with Good Laboratory
Practice and has been extensively documented, the cell banks
meet all pertinent United States and European Economic Commu-
nity regulatory requirements and importantly (from a production
standpoint), they can be grown in suspension to high cell densities
(up to 1  107 cells/ml) in serum-free medium. These cells were
shown to readily produce 300–500 mg/L of IgG without any media
or feed optimization [35].
2.4. CAP/CAP-T
Similar to the PER.C6 line, CEVEC’s Amniocyte Production (CAP)
cell line was originally developed for adenovirus production bytransforming primary human amniocytes (obtained transabdomi-
nally by amniocentesis) using the E1 functions of Ad5 [36]. A var-
iant of this line, CAP-T, was generated which constitutively
expresses the SV40 large T antigen in order to make them suitable
as a host for transient gene expression using plasmids carrying the
SV40 ori; this line is capable of expressing and secreting previously
difﬁcult-to-express protein targets [37]. It is hypothesized that the
stem cell-like origin of CAP cells may lead to a different or larger
repertoire of processing enzymes and chaperones compared to
more differentiated production cell lines. This hypothesis is sup-
ported by the example of the bone morphogenetic protein (BMP)
antagonist protein which failed to be secreted from HEK 293 cells
(where it was located in the insoluble fraction) but was success-
fully secreted into the medium by CAP cells. The yields of a few
other test proteins (secreted embryonic alkaline phosphatase, SEAP
and a kinase receptor extracellular domain) seem to indicate that
the CAP-T cells are at least as good as the HEK 293-E cells, if not
a little better, and superior to CHO cells [37].3. Advances in gene delivery/integration
Transient transfection followed by drug selection has been the
traditional method for DNA delivery and integration for creating
producer lines. While successful, this is often a slow (4–6 months)
and tedious process and the last decade has seen an increase in no-
vel and sophisticated approaches for enhancing the efﬁciency of
delivery and reducing the timeline for obtaining a producer cell
line (Fig. 2).3.1. Transient gene expression (TGE)
One strategy to accelerate the protein production process is to
eliminate the drug selection step by performing transient transfec-
tions at scale. Using this approach, clonal cell lines are not necessary
as cells are directly cultured (and transfected) at the production
scale and therefore do not need to be cultivated for long periods
of time. The use of suspension adapted HEK and CHO lines, along
with optimized commercialmedia, as well as the use of inexpensive
transfection agents (such as calcium phosphate and polyethyleni-
mine, PEI) has made large scale transient transfection an attractive
and successful approach (reviewed in [38,39]). Transfection at scale
implies culture volumes ranging from several hundredmilliliters in
shake ﬂasks or square bottles [40] to several hundred liters in stirred
tank bioreactors, orbital shakers [41] or Wave™ reactors [42].
One of the drawbacks of this approach is the need for multi-mil-
ligram quantities of recombinant plasmid DNA; however, obtain-
ing decigram quantities of plasmid DNA from a few liters of
E. coli is fairly routine [38]. It should be noted that the quality of
the DNA used for transfection can be an important factor; while
the quality may not be of critical importance for most TGE exper-
iments, it can be essential for the production of clinical grade pro-
teins where endotoxin and other contaminants need to be
minimized or eliminated [43,44].
As for the transfection reagent, 25 kDa linear PEI is the most
commonly used in TGE approaches and has a long and successful
track record [45–47]. While most transfections are performed at
cell densities of 1  105–1  106 cells/ml, recent reports have
shown enhanced production with high density transfection. For
example, CHO cells transfected at 4  106 cells/ml produced up
to 250 mg of antibody at scale in 14 days [48] and HEK 293 cells
transfected at densities as high as 2  107 cells/ml resulted in a
doubling of product titer [49]. Of note, the latter study involved di-
rect transfection, in which DNA and PEI were added directly to the
culture without a priori complex formation, resulting in improved
ease of handling and reduced transfection variability.
Fig. 2. Timelines for gene delivery and production methods. Standard protocol for generating stable producer lines and scaling up to bioreactor scale shown on top. This
process is compared to transient gene expression (TGE), Recombinase mediated cassette exchange (RMCE) and Lentivirus driven integration (LVs).
256 A.D. Bandaranayake, S.C. Almo / FEBS Letters 588 (2014) 253–260Once a transient production cell line has been established, sev-
eral strategies are available for maximizing protein expression.
These approaches, while useful in stable producer lines, are espe-
cially important in a transient setting where the culture period is
generally limited to 10–14 days. One method involves the over-
expression of anti-apoptotic proteins, such as bcl-2 family mem-
bers [50–52] and Bcl-x(L) [53,54], which leads to higher viability
and improved yields. Another approach is to induce cell cycle
arrest thereby improving productivity; this strategy can be accom-
plished either chemically using anti-mitotic agents (such as
hydroxyurea, nocodazole, colchicine, paclitaxel or vinblastine)
[55] or genetically by targeting cell cycle inhibitors such as p18,
p21 or p27Kip1 [38]. Growth factors such as acidic Fibroblast
Growth Factor (aFGF) or recombinant insulin-like growth factor
(LR3-IGF) can also increase cell densities and improve yield. DNA
methyltransferase inhibitors and histone deacetylase inhibitors
such as valproic acid and sodium butyrate have also been shown
to improve recombinant protein yields in transient settings [56].
Ultimately, a combination of factors may be necessary to achieve
the desired enhancement, such as those utilized in the ‘XLG proto-
col’ that involves over-expression of p18 and p21, expression of
aFGF and addition of Valproic Acid. These modiﬁcations result in
antibody production that exceeds 1 g/L in HEK 293-E cells, a 27-
fold improvement over standard approaches [31].
3.2. Recombinase mediated cassette exchange (RMCE)
Integration of exogenous DNA into a host chromosome is for the
most part a random event. As a result, most integrations are unpro-
ductive as only a small proportion of a cell’s genome (0.1%) is ac-
tively transcribed. Therefore, if the recombinant construct can be
targeted to an active and stable region (hotspot) of the genome
then even a single integration at such a favorable site can lead to
higher production yields than multiple integrations at sub-optimal
regions of the genome [57]. This idea led to the development of
RMCE, initially as a means of developing transgenic mouse models
(reviewed in [58]), but more recently for the generation of stableproducer lines for recombinant proteins. In brief, this strategy in-
volves the development of a master cell line that contains a single
integration of a reporter gene at a hotspot ﬂanked by integration
target sequences such as Flp recognition target sites (FRT) or loxp
sites (for the Cre system). The gene of interest can then be intro-
duced into this line in the presence of the appropriate recombinase
leading to the exchange of the reporter gene with the target gene,
‘‘Flp-out’’ or ‘‘Cre-out’’ [59]. The use of adeno- or non-integrating
lentivirus has also been shown to facilitate this reaction [60,61].
While this system promises to improve the speed and efﬁciency
with which producer lines can be generated, the actual improve-
ment in yields reported to date has only been moderate [62].
3.3. Viral delivery
Lentiviral vectors (LVs) derived from human immunodeﬁciency
virus type-1 (HIV-1) have a long history of efﬁcient gene delivery
in gene therapy applications [63]. Given the efﬁciency with which
LVs are capable of transducing a broad range of cell types, it is not
surprising that LVs have been recently used as a gene delivery tool
for protein production. The ‘Daedalus’ system has shown promis-
ing results for the rapid generation of stable producer lines in
HEK 293 Freestyle cells (Invitrogen), with yields of 20–100 mg/L
reported for a variety of secreted proteins without the need for clo-
nal selection [64]. LVs have also been used in the CHO platform
where certain clones were shown to produce as much as 200 mg/
L of the human tumor necrosis factor receptor-Fc fusion protein
[65]. One of the drawbacks of the LV system is the modest packag-
ing size of the lentivirus capsid (10 kilobases), which may limit
the maximum size of the recombinant protein being expressed.
3.4. Enhancement of protein production using UCOE, SAR and MAR
elements
Major factors contributing to the loss of productivity over time
are the positional effects that an integrated gene experiences in the
context of the host genome. To overcome the effects of silencing
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elements have been developed, including scaffold or matrix attach-
ment regions (S/MARs) and Ubiquitous Chromatin Opening Ele-
ments (UCOEs) [66]. S/MARs are DNA sequences which serve as
attachment points to the nuclear matrix, thus maintaining a trans-
criptionally active chromatin structure. These sequences have also
been shown to enhance DNA demethylation, making genes more
accessible to the transcriptional machinery [67,68]. MARs have
also been shown to serve as binding sites for transcription factors
like CCCTC binding factor (CTCF) and nuclear matrix proteins
(NMP) that enhance gene expression [69–71]. The b-interferon
SAR, human b-globin MAR and chicken lysozyme MAR have been
shown to promote stable protein expression (as long as 6 months)
and increase the occurrence of high producing clones, thereby
reducing the need for clonal selection [72–75].
UCOEs (Merck Millipore) are methylation-free CpG-rich se-
quences that help maintain chromatin in an ‘open’ conformation,
resulting in signiﬁcantly reduced silencing. These sequences en-
hance protein expression over extended periods of time in
in vitro transfection experiments [76,77], as well as in gene therapy
settings [78,79]. While effective UCOE elements tend to be in the
2–4 kb range, it is notable that the Daedalus system uses the small-
est UCOE sequence described to date (0.7 kb), with activity that is
equivalent to the larger fragments [64]. The use of UCOEs in pro-
ducer line development has shown a 3–6 fold improvement in pro-
tein yield over several months of culture [64,80].4. Advances in selection methodology
The traditional methods of integration followed by drug selec-
tion for generating stable producer lines can be tedious and time
consuming, often taking several months. Further, increasing the
dose of selection agent in order to select for higher producing
clones can lead to a loss of successful clones due to the slower
growth of these cells at high drug concentration. As a result, there
have been considerable efforts to increase the speed and efﬁciency
of selection methods and to enhance the ﬁnal producer yields.4.1. Destabilized selection markers
An attractive alternative to increasing selection pressure by
increasing the concentration of the drug is to attenuate the activity
of the selection marker so that high producer lines are still efﬁ-
ciently selected at lower doses of the drug. The hope is to reduce
the undesirable side-effects of the drug (e.g. slow cell growth)
while maintaining sufﬁcient selection pressure to obtain highly
producing clones. This strategy is exempliﬁed by the introduction
of mutations into the neomycin phosphotransferase II selection
marker (Neo), which results in reduced afﬁnity for the selection
drug neomycin. This approach led to an improvement in monoclo-
nal antibody production from between 6- to 17-fold [66,81,82].
Alternatively, mutation of the Neo selection gene can be avoided
by placing the gene under the control of a weak promoter (Herpes
simplex virus thymidine kinase), which reduces transcription and
availability of Neo [83]. Another approach is to re-engineer the
resistance sequence to contain the least preferred codons of the
host organism (i.e., ‘de-optimization’) in order to lower transla-
tional efﬁciency and reduce the cellular concentration of the resis-
tance protein (e.g., dihydrofolate reductase; DHFR) [84].
One of the most popular selection systems in current use is
methotrexate (MTX) ampliﬁcation with DHFR-deﬁcient CHO cells
[12,13,62,66,85]. The DHFR-deﬁcient CHO cells (CHO-DG44) were
created by gamma-ray induced mutation of CHO cells and require
the presence of glycine, hypoxanthine and thymidine to survive
[21,86]. Once the cells are transfected with the gene of interest(linked to the DHFR selection gene), hypoxanthine and thymidine
are withdrawn from the culture medium to select for the success-
ful transfectants. Further selection pressure is introduced by the
addition of MTX to the culture which acts as a competitive inhibi-
tor of DHFR and promotes MTX ampliﬁcation, selecting for cells
with higher copy numbers (and therefore productivity) of the
DHFR gene and associated target gene [87]. In order to weaken
the selection marker, and therefore increase stringency, Yap and
colleagues investigated destabilizing the mRNA, as well as the
DHFR protein [88]. Their strategy was to introduce short AU rich
elements (AREs) into the mRNA which constitutively destabilizes
the mRNA. In a further modiﬁcation, the murine ornithine decar-
boxylase (MODC) PEST sequence was added to the dhfr gene,
resulting in higher turnover of the protein. The authors tested this
strategy with the expression of interferon gamma (IFNc) and found
that 1.7-, 6.6- and 13.3-fold improvements in speciﬁc IFNc produc-
tivities were obtained with the application of ARE, MODC PEST, and
both ARE and MODC PEST, respectively. In an attempt to more clo-
sely link the gene of interest and selection marker (thereby pre-
venting the possibility of gene fragmentation and loss of the
target gene), Lam and colleagues introduced the dhfr gene directly
downstream of the gene of interest using an Internal Ribosome En-
try Sequence (IRES) [89]. This strategy allowed for both genes to be
translated off of the same RNA; in addition, the stringency of selec-
tion was further increased by adding the PEST sequence to the dhfr
gene.
The glutamine synthetase (GS) system is another method of
gene ampliﬁcation, which has been successfully used with GS-neg-
ative NS0 cells [90], as well as GS-expressing CHO cells [91]. The
CHO cells, containing an endogenous GS gene, need to be treated
with the GS enzyme inhibitor methionine sulfoximine (MSX) to
suppress the activity of endogenous GS. Increasing levels of MSX
can then be used to select for clones with a high copy number of
the selection gene and ﬂanking target gene. This method has been
used to drive target gene copy number in CHO cells to as many as
200 copies [92]. A fortuitous advantage of this system is that these
cells do not require glutamine supplementation in the media, and
as a result the culture does not accumulate high levels of toxic
ammonia. The GS system has been recently enhanced with the
development of a GS-knockout CHO line (CHOK1SV) that led to a
signiﬁcant increase in selection stringency and a 6-fold improve-
ment in the efﬁciency of identifying similar numbers of highly pro-
ductive cell lines (compared to the standard protocol) for a
given recombinant monoclonal antibody [93].
4.2. Fluorescence-activated cell sorting (FACS)-based screening
Flow cytometry is a powerful technology that allows for the ra-
pid, objective and sensitive multiparametric analysis of cells [94].
In addition to its analytical capabilities, ﬂow cytometry also allows
for the separation of the analyzed cells. In a ﬂow cytometer cells
pass in a single stream, one by one, in front of a laser. The laser
then interrogates the stream of cells for different morphologic,
structural and ﬂuorescent properties of the cell. At present as many
as a dozen or more of these characteristics can be acquired for each
cell passing through the cytometer, providing a wealth of informa-
tion regarding the health and various other user-deﬁned parame-
ters of each cell. While most cytometers are devoted solely to
analysis, many can also sort cells based on characteristics that
the user would like to obtain, making the sorting of transfection
positive cells (detected by an associated ﬂuorescent reporter) rou-
tine. Recently, high-throughput cytometers, such as the HyperCyt
(Intellicyt), have dramatically increased the speed with which cell
populations can be interrogated for user-deﬁned characteristics
[95,96]. Flow cytometers can be used to sort cells at the single-cell
level, depositing 1 cell/well of a 96-well plate, or can be used for
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porter positive cells; allowing for the creation of clonal or oligocl-
onal populations in a matter of hours.
A non-invasive technique termed ‘cold capture’ has recently
been developed to detect the amount of recombinant protein being
secreted by a producer line. In this approach cells are incubated on
ice (4 C) to slow the secretion process and a ﬂuorescent antibody
is used for the FACS-based detection of recombinant proteins
‘trapped’ on the cell surface [97]. The top FACS-isolated clones
can show a 5- to 7-fold increase in yield. Further work showed that
the same process can be performed at room temperature (21 C)
and that use of phycoerythrin (PE) as a ﬂuorophore for detecting
the secreted protein was superior to ﬂuorescein isothiocyanate
(FITC) in terms of stability of the signal [98].
An alternate non-invasive strategy is the use of FITC-labeled
methotrexate (F-MTX) to bind an intracellular DHFR selection mar-
ker [99]. This strategy allowed for the rapid isolation of gene
ampliﬁed cells from a heterogeneous pool.5. Summary
Given the rapid pace at which new cell lines, media formula-
tions, gene delivery and clonal selection techniques are emerging,
the production of proteins for basic research and pharmaceutical
use will continue to beneﬁt from enhanced efﬁciencies and re-
duced costs. While transient transfection has experienced a revival
due to optimization of large scale and high density transfection
techniques, alternate methods of gene delivery such as RMCE and
viral platforms have increased the options available. When com-
bined with sophisticated selection methods, these approaches
readily enable the screening of large numbers of target variants
for expression or the production of gram quantities of a therapeutic
target. The advent of novel human production cell lines continues
to push the boundaries of the targets that can be expressed, their
quality and total yields. It would not be surprising if the reliance
on CHO cells for therapeutic production starts to wane as pharma-
ceutical companies invest in and embrace these new cell lines; it is
estimated that there are already more than a dozen PER.C6-based
products in Phase I/II clinical trials [100].
Despite the increasing number of protein production platforms
available for use, there is no ‘magic bullet’ capable of meeting all
challenges. The idiosyncratic behavior of each protein and the
eventual downstream applications, along with cost and ease of
use, drive the decision towards one platform or another. The
large-scale NYSGRC structure and function discovery program uses
a combination of platforms (E. coli, insect and mammalian cells) to
produce target proteins. While most groups cannot or will not take
such a broad approach to protein production, the options within a
given platform are continuously expanding. Therefore, a limitation
of protein production, at the moment, seems to be associated with
the complexity of targets that can be imagined rather than produc-
tion techniques available.
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